| Autor: |
Falade-Nwulia, Oluwaseun, Lesko, Catherine R, Fojo, Anthony T, Keruly, Jeanne C, Moore, Richard D, Sutcliffe, Catherine G, Mehta, Shruti H, Chander, Geetanjali, Thomas, David L, Sulkowski, Mark |
| Zdroj: |
Journal of Infectious Diseases; 3/15/2024, Vol. 229 Issue 3, p775-779, 5p |
| Abstrakt: |
Access to direct acting antivirals (DAAs) may be associated with reductions in hepatitis C virus (HCV) viremia prevalence among people with human immunodeficiency virus (PWH). Among 3755 PWH, estimated HCV viremia prevalence decreased by 94.0% from 36% (95% confidence interval [CI], 27%–46%) in 2009 (pre-DAA era) to 2% (95% CI, 0%–4%) in 2021 (DAA era). Male sex, black race, and older age were associated with HCV viremia in 2009 but not in 2021. Injection drug use remained associated with HCV viremia in 2009 and 2021. Targeted interventions are needed to meet the HCV care needs of PWH who use drugs. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
